Titan Pharmaceuticals Inc (TTNP)

[KMBJN]

Interesting Braeburn presentation. I didn't realize that the other implantable form of buprenorphine (Camurus' FluidCrystal weekly and monthly injectable subcutaneous gels) is projected to have 2x the sales of probuphine implant for both opioid addiction and pain: $300M probuphine vs. $600M CMX for OA, $250M prob vs $500M peak sales for pain. The anticipated Camerus product approval is about 2 years behind for opioid addiction, but both products might be launched in 2018 for pain.

Some could interpret this as a conflict of interest for Titan / probuphine, that perhaps Braeburn could promote the other implant more intensely for some reason. I'm not sure what the reason would be, however, as apparently Braeburn licensed both technologies under similar terms - high teen + % royalties, so I suppose Braeburn would be happy with all sales equally. Perhaps there would be some synergy for probuphine, but I mostly see it as a negative to have this competition.

Some think Braeburn would buy out / merge with Titan. What about Camerus, would they buy / merge with them too?

I guess we should just hope first that probuphine gets approved this time around, both for us TTNP investors and for the good of society - to remove so much abusable narcotic that is out there.